tetano
Editor, Senior Moderator
Nat Rev Gastroenterol Hepatol
. 2022 Oct 21.
doi: 10.1038/s41575-022-00698-4. Online ahead of print.
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications
Raphaela I Lau[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Fen Zhang[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Qin Liu[SUP] 1 2 3 [/SUP], Qi Su[SUP] 1 2 3 [/SUP], Francis K L Chan[SUP] 1 2 3 [/SUP], Siew C Ng[SUP] 4 5 6 [/SUP]
Affiliations
Abstract
The gastrointestinal tract is involved in coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The gut microbiota has important roles in viral entry receptor angiotensin-converting enzyme 2 (ACE2) expression, immune homeostasis, and crosstalk between the gut and lungs, the 'gut-lung axis'. Emerging preclinical and clinical studies indicate that the gut microbiota might contribute to COVID-19 pathogenesis and disease outcomes; SARS-CoV-2 infection was associated with altered intestinal microbiota and correlated with inflammatory and immune responses. Here, we discuss the cutting-edge evidence on the interactions between SARS-CoV-2 infection and the gut microbiota, key microbial changes in relation to COVID-19 severity and host immune dysregulations with the possible underlying mechanisms, and the conceivable consequences of the pandemic on the human microbiome and post-pandemic health. Finally, potential modulatory strategies of the gut microbiota are discussed. These insights could shed light on the development of microbiota-based interventions for COVID-19.
. 2022 Oct 21.
doi: 10.1038/s41575-022-00698-4. Online ahead of print.
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications
Raphaela I Lau[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Fen Zhang[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Qin Liu[SUP] 1 2 3 [/SUP], Qi Su[SUP] 1 2 3 [/SUP], Francis K L Chan[SUP] 1 2 3 [/SUP], Siew C Ng[SUP] 4 5 6 [/SUP]
Affiliations
- PMID: 36271144
- DOI: 10.1038/s41575-022-00698-4
Abstract
The gastrointestinal tract is involved in coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The gut microbiota has important roles in viral entry receptor angiotensin-converting enzyme 2 (ACE2) expression, immune homeostasis, and crosstalk between the gut and lungs, the 'gut-lung axis'. Emerging preclinical and clinical studies indicate that the gut microbiota might contribute to COVID-19 pathogenesis and disease outcomes; SARS-CoV-2 infection was associated with altered intestinal microbiota and correlated with inflammatory and immune responses. Here, we discuss the cutting-edge evidence on the interactions between SARS-CoV-2 infection and the gut microbiota, key microbial changes in relation to COVID-19 severity and host immune dysregulations with the possible underlying mechanisms, and the conceivable consequences of the pandemic on the human microbiome and post-pandemic health. Finally, potential modulatory strategies of the gut microbiota are discussed. These insights could shed light on the development of microbiota-based interventions for COVID-19.